Althea Technologies offers formulation development services

Nov 5 2009

Althea Technologies, Inc., a leading provider of development and manufacturing services for biopharmaceutical products announced the addition of customized Formulation Development to the company's platform of services, which will be overseen by the newly appointed Dr. James Matsuura, Director of Formulation Development. This investment in an experienced team of formulation and analytical scientists, along with new laboratory facilities and state-of-the-art equipment, enhances and complements Althea's existing expertise and capabilities in cGMP biologics manufacturing and aseptic filling of injectable products, and completes the full integration of development and manufacturing services available for clients from early-stage development through commercial supply.

The new formulation laboratories are an expansion to the clinical manufacturing facility located on the San Diego campus and are further supported by the analytical expertise of Windrose Analytica, which was acquired by Althea earlier this year. "The addition of our new formulation development laboratories is the perfect complement to our advanced protein and peptide analytical capabilities, and will allow us to bring our clients' products into the clinic with unmatched speed, efficiency and effectiveness," noted Dr. Alan Herman, Vice President of Product Development & Chief Scientific Officer.

"We are delighted to have Dr. James Matsuura join Althea. His many years of experience bring added value to clients in helping them with the complexities of developing protein formulations for both clinical trials and product launch in our new commercial manufacturing facility," commented Dr. Shabbir Anik, Althea President and Chief Executive Officer, on the appointment of Dr. James Matsuura as Director of Formulation Development.

Althea's formulation development scientists are experienced in developing both liquid and lyophilized formulations, to ensure that a stable product is delivered to the clinical site and the patient. The expanded facilities include a new development lyophilizer, which allows the group to optimize lyophilization cycles for products requiring enhanced stability. The new formulation laboratory and staff, operating closely with the analytical development group, complete Althea's product development group and enable Althea to support clients with critical development steps, as well as the manufacture of API and finished product.